Nanjing King-friend Biochemical Pharmaceutical Co 603707.SS · CNY
Health Care · Shanghai · 🇨🇳 China
8.75
-1.46%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nanjing King-friend Biochemical Pharmaceutical Co
Its shares trade on Shanghai under the ticker 603707.SS. It has been listed since 19 July 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.99bn and net income of CN¥581.5m. At that date it held total assets of CN¥10.34bn and shareholders' equity of CN¥6.90bn.
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. is a holding company that engages in the research, development, manufacture and sale of biochemical pharmaceutical products. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2017-07-19. The firm's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The firm mainly exports its products to the United States and European countries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Jul 2017
- Employees
- 1,396
- Website
- nkf-pharma.com ↗
Leadership
Pay as last reported
- Mr. Yongqun TangChairman of the Board, General Manager, since 2017CN¥1.5m
- Ms. Xiaojie QianFinance DirectorCN¥714,000
- Mr. Xiwei HuangDeputy General Manager, Secretary of the Board, Director, since 2022CN¥1.1m
- Ms. Guiping WuDeputy General ManagerCN¥599,000
- Ms. Juhua XieDirector
- Mr. Guoqing CuiIndependent DirectorCN¥80,000
- Mr. Yi JinIndependent DirectorCN¥80,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 18
- Environment
- 13
- Social
- 14
- Governance
- 28
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is a holding company engaged in research, development, manufacture, and sale of biochemical pharmaceutical products.
- Headquartered in Nanjing, Jiangsu with 1,396 full-time employees.
- Main products include standard heparin raw materials, low molecular weight heparin raw materials, and their preparations.
Weaknesses
- Company is a holding company with no specific product details provided beyond the main products listed.
- No information on financial performance or market share is available.
- Dependent on exports to the United States and European countries for revenue.
Opportunities
- Potential to expand product lines beyond heparin-related products.
- Growing demand for pharmaceutical products in global markets.
- Opportunity to increase market share in existing export markets.
Threats
- Reliance on exports to the United States and European countries may expose the company to geopolitical risks.
- Competition from other pharmaceutical companies in the global market.
- Potential regulatory changes affecting export markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.